Geron Corp - Company Profile
Powered by 
All the data and insights you need on Geron Corp in one report.
$295
- Save hours of research time and resources with
our up-to-date Geron Corp Strategy Report
- Understand Geron Corp position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Geron Corp Catalyst Calendar
Proactively evaluate Geron Corp’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.
A sample of Geron Corp Catalyst Calendar data
| Event Date | Event Type | Company Name | Ticker Symbol | Drug Name | Therapy Area | Indication | Source Type |
|---|---|---|---|---|---|---|---|
| 01 Jan 2023 | GDCTWXYZ | Lorem | Lorem | Lorem | WXYZ | Planned | Lorem |
| 31 Dec 2022 | Phase I/II Trial Results | California Institute for Regenerative Medicine; Geron Corp; Lineage Cell Therapeutics Inc | GERN; LCTX | OPC-1 | Central Nervous System | Acute Spinal Cord Injury; Spinal Cord Injury; Traumatic Spinal Cord Injury | Company Press Release |
| 01 Dec 2022 | Phase II Trial Initiation | Australasian Leukaemia and Lymphoma Group; European Myelodysplastic Syndromes Cooperative Group; GCP-Service International Ltd & Co KG; Geron Corp; Groupe Francophone des Myelodysplasies; QIMR Berghofer Medical Research Institute; Saint-Louis Hospital; University Hospital Leipzig | GERN | imetelstat sodium | Oncology | Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia); Myelodysplastic Syndrome; Refractory Acute Myeloid Leukemia; Relapsed Acute Myeloid Leukemia | Clinical Trial Registry |
| 01 Jun 2022 | Phase I Trial Initiation | Geron Corp | GERN | imetelstat sodium; ruxolitinib phosphate | Oncology | Myelofibrosis; Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF); Post-Polycythemia Vera Myelofibrosis (PPV-MF) | Clinical Trial Registry |
Feature
Catalyst Calendar provides forecasted drug development milestones within the Pharma industry including expected timing, expected outcomes and possible financial impacts.
Benefit
Access:
- Trial Events for trials conducted globally by a company, university, institute or CRO: Trial Initiation, Trial Completion, Trial Results
- Regulatory Events related to drug filings with regulatory bodies, approvals and commercial launches. This is covered for the US, EU and Japan
- Intellectual Property Events for patent and exclusivity expiry specific to the US, EU and Japan: Constraining Patent Expiry (US/EU/Japan), Drug Expiry (US/EU/Japan), Commercial Launch (US/EU/Japan)
Value
Proactively evaluate companies and catalyst impacts
Stay ahead of the competition & improve corporate planning
Bolster business development with timely opportunities
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer